Marie-Christine Alessi

List of Publications by Year
in descending order

329	24,579	6613 79	8167 148
papers	citations	h-index	g-index

352	352	352	24282
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metabolic Endotoxemia Initiates Obesity and Insulin Resistance. Diabetes, 2007, 56, 1761-1772.	0.6	4,964
2	Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia, 1991, 34, 457-462.	6.3	549
3	Energy intake is associated with endotoxemia in apparently healthy men. American Journal of Clinical Nutrition, 2008, 87, 1219-1223.	4.7	498
4	Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism: Clinical and Experimental, 1986, 35, 250-253.	3.4	442
5	Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris. Circulation, 1996, 94, 2057-2063.	1.6	437
6	High postâ€treatment platelet reactivity identified lowâ€responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2006, 4, 542-549.	3.8	349
7	Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis. Thrombosis and Haemostasis, 1987, 57, 067-072.	3.4	343
8	PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events. Thrombosis and Haemostasis, 1997, 78, 656-660.	3.4	330
9	Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. Journal of the American College of Cardiology, 2006, 48, 1339-1345.	2.8	329
10	PAI-1 and the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2200-2207.	2.4	326
11	Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes, 2000, 49, 1374-1380.	0.6	322
12	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 38, 3070-3078.	2.2	316
13	Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. Journal of Thrombosis and Haemostasis, 2003, 1, 1575-1579.	3.8	315
14	C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia, 2007, 50, 1267-1276.	6.3	309
15	Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood, 2009, 113, 5298-5303.	1.4	283
16	Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nature Genetics, 2011, 43, 735-737.	21.4	245
17	Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood, 1996, 88, 410-416.	1.4	240
18	Expression of the mRNA Coding for 11Î²-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: Anin SituHybridization Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2701-2705.	3.6	220

#	Article	IF	Citations
19	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. JAMA Psychiatry, 2018, 75, 396.	11.0	214
20	Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. Journal of the American College of Cardiology, 2009, 54, 1149-1153.	2.8	212
21	Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.. Arteriosclerosis (Dallas, Tex), 1989, 9, 362-367.	4.9	205
22	Endothelial Cell Markers and the Risk of Coronary Heart Disease. Circulation, 2004, 109, 1343-1348.	1.6	203
23	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 2007, 98, 838-843.	3.4	203
24	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. American Journal of Cardiology, 2008, 101, 1088-1093.	1.6	194
25	Expression of the mRNA Coding for 11Â-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An in Situ Hybridization Study. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2701-2705.	3.6	186
26	Stromal Cells Are the Main Plasminogen Activator Inhibitor-1-Producing Cells in Human Fat. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 173-178.	2.4	182
27	Granulocyte-endothelium initial adhesion. Analysis of transient binding events mediated by E-selectin in a laminar shear flow. Biophysical Journal, 1993, 64, 1922-1933.	0.5	180
28	Effects of Bariatric Surgery on Cardiac Ectopic Fat. Journal of the American College of Cardiology, 2012, 60, 1381-1389.	2.8	175
29	Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes, 1997, 46, 860-867.	0.6	175
30	Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Current Opinion in Lipidology, 2007, 18, 240-245.	2.7	174
31	Plasminogen Activator Inhibitor 1 and Atherothrombosis. Thrombosis and Haemostasis, 1993, 70, 138-143.	3.4	171
32	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis and Haemostasis, 2009, 7, 49-57.	3.8	169
33	Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1262-1268.	2.4	168
34	Metabolic syndrome, haemostasis and thrombosis. Thrombosis and Haemostasis, 2008, 99, 995-1000.	3.4	163
35	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	1.4	157
36	Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects. Thrombosis and Haemostasis, 1987, 57, 326-328.	3.4	152

#	Article	IF	Citations
37	ANKRD26-related thrombocytopenia and myeloid malignancies. Blood, 2013, 122, 1987-1989.	1.4	145
38	Identification of polymorphisms in the promoter and the 3â€² region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood, 2001, 97, 2053-2058.	1.4	140
39	Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders. JACC: Cardiovascular Interventions, 2008, 1, 649-653.	2.9	140
40	Thrombogenic and Fibrinolytic Factors and Cardiovascular Risk in Non-insulin-dependent Diabetes Mellitus. Annals of Medicine, 1996, 28, 371-380.	3.8	138
41	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 867-873.	2.4	137
42	Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism: Clinical and Experimental, 1989, 38, 913-915.	3.4	135
43	Epicardial Adipose Tissue Extent: Relationship With Age, Body Fat Distribution, and Coronaropathy. Obesity, 2008, 16, 2424-2430.	3.0	134
44	Genetics of Venous Thrombosis: Insights from a New Genome Wide Association Study. PLoS ONE, 2011, 6, e25581.	2.5	127
45	Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1150-1154.	2.4	124
46	Spectrum of the Mutations in Bernard-Soulier Syndrome. Human Mutation, 2014, 35, 1033-1045.	2.5	124
47	Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 84-91.	2.4	123
48	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.. EuroIntervention, 2009, 5, 325-329.	3.2	123
49	Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia, 2001, 44, 2025-2031.	6.3	122
50	Potential Contribution of Adipose Tissue to Elevated Serum Cystatin C in Human Obesity. Obesity, 2009, 17, 2121-2126.	3.0	122
51	Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. Thrombosis and Haemostasis, 2013, 110, 669-680.	3.4	121
52	Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.. Diabetes, 1999, 48, 890-895.	0.6	117
53	Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Molecular Biology, 2008, 9, 26.	3.0	117
54	Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. Journal of Experimental Medicine, 2014, 211, 1349-1362.	8.5	117

#	Article	IF	Citations
55	The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2009, 7, 1409-1411.	3.8	114
56	Microparticle increase in severe obesity: Not related to metabolic syndrome and unchanged after massive weight loss. Obesity, 2013, 21, 2236-2243.	3.0	114
57	Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Interventionâ€â€Conflicts of interest: Dr. Angiolillo is a consultant and on the speakerâ€™s bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received research grants from Sa. American Journal of Cardiology, 2007, 100, 1199-1206.	1.6	110
58	Chlamydia pneumoniaeDNA Detection in Peripheral Blood Mononuclear Cells Is Predictive of Vascular Infection. Journal of Infectious Diseases, 1999, 180, 2074-2076.	4.0	108
59	Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal, 1995, 8, 1352-1356.	6.7	105
60	Microparticles of Human Atherosclerotic Plaques Enhance the Shedding of the Tumor Necrosis Factor-Î± Converting Enzyme/ADAM17 Substrates, Tumor Necrosis Factor and Tumor Necrosis Factor Receptor-1. American Journal of Pathology, 2007, 171, 1713-1723.	3.8	105
61	The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes. Diabetologia, 2009, 52, 1152-1163.	6.3	104
62	Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. FASEB Journal, 2009, 23, 3449-3458.	0.5	103
63	High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thrombosis and Haemostasis, 2007, 97, 282-287.	3.4	102
64	PAI-1 Produced Ex Vivo by Human Adipose Tissue Is Relevant to PAI-1 Blood Level. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1361-1365.	2.4	99
65	Plasma TAFI Antigen Variations in Healthy Subjects. Thrombosis and Haemostasis, 2000, 83, 902-905.	3.4	99
66	Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls. Thrombosis and Haemostasis, 1994, 72, 044-053.	3.4	99
67	Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 1821-1829.	3.9	98
68	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood, 2012, 120, 2708-2718.	1.4	93
69	Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. International Journal of Obesity, 1998, 22, 312-317.	3.4	92
70	Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. Thrombosis and Haemostasis, 2007, 97, 949-954.	3.4	92
71	CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2012, 5, 1280-1287.	2.9	92
72	Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 78-84.	2.4	91

#	Article	IF	Citations
73	Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. International Journal of Obesity, 2012, 36, 422-430.	3.4	89
74	Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2156-2161.	2.4	86
75	Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet Journal of Rare Diseases, 2016, 11, 49.	2.7	86
76	Secretory Type II Phospholipase A2 Is Produced and Secreted by Epicardial Adipose Tissue and Overexpressed in Patients with Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 963-967.	3.6	85
77	Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. International Journal of Obesity, 2015, 39, 480-487.	3.4	84
78	The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: Possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis, 2006, 187, 82-91.	0.8	82
79	Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2209-2215.	2.4	82
80	Five Frequent Polymorphisms of the PAI-1 Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 851-858.	2.4	81
81	Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. British Journal of Haematology, 2005, 128, 91-99.	2.5	80
82	Development of a Genotype 325â€“Specific proCPU/TAFI ELISA. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1122-1127.	2.4	79
83	Aspirin noncompliance is the major cause of â€œaspirin resistanceâ€•in patients undergoing coronary stenting. American Heart Journal, 2009, 157, 889-893.	2.7	78
84	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thrombosis Research, 2007, 120, 893-899.	1.7	77
85	Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. Journal of Cellular and Molecular Medicine, 2012, 16, 1731-1738.	3.6	76
86	Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). FEBS Journal, 1988, 175, 531-540.	0.2	75
87	Procoagulant Platelets Form an Î±-Granule Protein-covered â€œCapâ€•on Their Surface That Promotes Their Attachment to Aggregates. Journal of Biological Chemistry, 2013, 288, 29621-29632.	3.4	74
88	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thrombosis Research, 2009, 123, 597-603.	1.7	72
89	Antibodies to Phosphatidylethanolamine as the only Antiphospholipid Antibodies Found in Patients with Unexplained Thromboses. Thrombosis and Haemostasis, 2001, 85, 800-805.	3.4	70
90	Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34 ⁺ progenitors. Haematologica, 2017, 102, 282-294.	3.5	70

#	Article	IF	Citations
91	Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. Journal of Thrombosis and Haemostasis, 2007, 5, 475-482.	3.8	68
92	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thrombosis and Haemostasis, 2007, 97, 212-217.	3.4	67
93	Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. JACC: Cardiovascular Interventions, 2013, 6, 854-863.	2.9	67
94	Expanding the Mutation Spectrum Affecting Î±IIbÎ²3 Integrin in Glanzmann Thrombasthenia: Screening of theITGA2BandITGB3Genes in a Large International Cohort. Human Mutation, 2015, 36, 548-561.	2.5	67
95	Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.. Journal of Clinical Investigation, 1993, 91, 2185-2193.	8.2	67
96	Predictive Values of Post-Treatment Adenosine Diphosphateâ€“Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. American Journal of Cardiology, 2009, 104, 1078-1082.	1.6	66
97	Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood, 2010, 115, 97-106.	1.4	66
98	Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2250-2257.	2.4	65
99	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. International Journal of Cardiology, 2013, 168, 568-569.	1.7	65
100	Platelet-endothelial cell interactions in cerebral malaria: The end of a cordial understanding. Thrombosis and Haemostasis, 2009, 102, 1093-1102.	3.4	64
101	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
102	On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. Journal of Thrombosis and Haemostasis, 2005, 3, 1174-1179.	3.8	62
103	Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity. Thrombosis and Haemostasis, 2001, 85, 1111-1116.	3.4	61
104	C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein Sâ€“independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. Blood, 2010, 115, 4644-4650.	1.4	61
105	The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 269-273.	0.3	60
106	A Novel Leukocyte Adhesion Deficiency III Variant: Kindlin-3 Deficiency Results in Integrin- and Nonintegrin-Related Defects in Different Steps of Leukocyte Adhesion. Journal of Immunology, 2011, 186, 5273-5283.	0.8	59
107	An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. Microbial Pathogenesis, 2012, 52, 61-68.	2.9	59
108	Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. American Journal of Cardiology, 2013, 111, 985-990.	1.6	59

#	Article	IF	Citations
109	High prevalence of laminopathies among patients with metabolic syndrome. Human Molecular Genetics, 2011, 20, 3779-3786.	2.9	58
110	Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. Journal of Internal Medicine, 2004, 255, 448-456.	6.0	57
111	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. American Journal of Human Genetics, 2010, 86, 592-595.	6.2	57
112	The A â^'844G Polymorphism in the PAI-1 Gene Is Associated With a Higher Risk of Venous Thrombosis in Factor V Leiden Carriers. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1387-1391.	2.4	55
113	Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. Journal of Thrombosis and Haemostasis, 2003, 1, 791-797.	3.8	55
114	Adipose Tissue and Atherothrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 290-297.	0.3	54
115	Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Archives of Cardiovascular Diseases, 2010, 103, 39-45.	1.6	53
116	KNG1 Ile581Thr and susceptibility to venous thrombosis. Blood, 2011, 117, 3692-3694.	1.4	53
117	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. Journal of Thrombosis and Haemostasis, 2003, 1, 2322-2329.	3.8	52
118	Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E995-E1002.	3.5	52
119	Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels. Thrombosis Research, 1990, 60, 509-516.	1.7	49
120	Two Types of Procoagulant Platelets Are Formed Upon Physiological Activation and Are Controlled by Integrin Î± _{IIb} Î² ₃. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2475-2483.	2.4	46
121	Regulation of Fibrinolysis in the Development of Atherothrombosis: Role of Adipose Tissue. Thrombosis and Haemostasis, 1999, 82, 832-836.	3.4	46
122	Potentiation by Heparin Fragments of Thrombolysis Induced with Human Tissue-Type Plasminogen Activator or Human Single-Chain Urokinase-Type Plasminogen Activator. Thrombosis and Haemostasis, 1987, 58, 947-950.	3.4	46
123	Fat Cell Function and Fibrinolysis. Hormone and Metabolic Research, 2000, 32, 504-508.	1.5	45
124	Effect of sleep apnea syndrome on the circadian profile of cortisol in obese men. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E466-E474.	3.5	42
125	A multiâ€stage multiâ€design strategy provides strong evidence that the BAI3 locus is associated with earlyâ€onset venous thromboembolism. Journal of Thrombosis and Haemostasis, 2010, 8, 2671-2679.	3.8	42
126	Progression of atherosclerosis in ApoEâ€deficient mice that express distinct molecular forms of TNFâ€alpha. Journal of Pathology, 2008, 214, 574-583.	4.5	41

#	Article	IF	Citations
127	Prasugrel Monitoring and Bleeding in Real World Patients. American Journal of Cardiology, 2013, 111, 38-44.	1.6	41
128	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 760-765.	1.6	40
129	Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. Journal of Thrombosis and Haemostasis, 2008, 6, 1494-1499.	3.8	39
130	Expression of the mRNAs Coding for the Glucocorticoid Receptor Isoforms in Obesity. Obesity, 2003, 11, 925-929.	4.0	38
131	HDLs activate ADAM17â€dependent shedding. Journal of Cellular Physiology, 2008, 214, 687-693.	4.1	38
132	Down-regulation of Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Expression Is Necessary for Adipocyte Differentiation. Journal of Biological Chemistry, 2010, 285, 6508-6514.	3.4	38
133	Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase. Journal of Cell Science, 2011, 124, 1224-1230.	2.0	38
134	Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding. Blood, 2017, 130, 1026-1030.	1.4	38
135	Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood, 2006, 108, 1562-1568.	1.4	37
136	Palmitoylation of TNF alpha is involved in the regulation of TNF receptor 1 signalling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 602-612.	4.1	37
137	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. JACC: Cardiovascular Interventions, 2017, 10, 2560-2570.	2.9	36
138	Fibrinolysis and risk of coronary artery disease. Fibrinolysis, 1996, 10, 127-136.	0.5	35
139	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. American Journal of Cardiology, 2014, 113, 54-59.	1.6	35
140	Risk factors for venous thromboembolism in women under combined oral contraceptive. Thrombosis and Haemostasis, 2016, 115, 135-142.	3.4	35
141	Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thrombosis and Haemostasis, 2005, 94, 373-9.	3.4	34
142	Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Thrombosis and Haemostasis, 2011, 106, 416-422.	3.4	34
143	Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus Infections. Journal of Infectious Diseases, 2016, 214, 237-247.	4.0	34
144	Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features. Haematologica, 2017, 102, 1006-1016.	3.5	34

#	Article	IF	Citations
145	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	1.4	34
146	The increased plasma Lp(a) : B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. Clinica Chimica Acta, 1990, 188, 119-127.	1.1	33
147	Daytime Fluctuations of Plasminogen Activator Inhibitor 1 (PAI-1) in Populations with High PAI-1 Levels. Thrombosis and Haemostasis, 1992, 67, 076-082.	3.4	33
148	Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells. Infection and Immunity, 1990, 58, 2459-2463.	2.2	33
149	Relationships between Fibrinolytic and Inflammatory Parameters in Human Adipose Tissue: Strong Contribution of TNFÎ± Receptors to PAI-1 Levels. Thrombosis and Haemostasis, 2002, 88, 481-487.	3.4	32
150	Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?. Immunobiology, 2007, 212, 557-565.	1.9	32
151	Platelets Alter Gene Expression Profile in Human Brain Endothelial Cells in an In Vitro Model of Cerebral Malaria. PLoS ONE, 2011, 6, e19651.	2.5	32
152	Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Thrombosis and Haemostasis, 2016, 115, 823-825.	3.4	32
153	From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. Journal of Medicinal Chemistry, 2018, 61, 7202-7217.	6.4	32
154	Fibrinolytic function and coronary risk. Current Cardiology Reports, 1999, 1, 119-124.	2.9	28
155	A Novel Missense Mutation Shows that GPIbÎ² Has a Dual Role in Controlling the Processing and Stability of the Platelet GPIb-IX Adhesion Receptor. Biochemistry, 2003, 42, 4452-4462.	2.5	27
156	Expression of adrenomedullin in adipose tissue of lean and obese women. European Journal of Endocrinology, 2006, 155, 177-185.	3.7	27
157	Paraoxonase-1 and clopidogrel efficacy. Nature Medicine, 2011, 17, 1039-1039.	30.7	27
158	A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential. Blood, 2014, 123, 777-785.	1.4	27
159	FPR2: A Novel Promising Target for the Treatment of Influenza. Frontiers in Microbiology, 2017, 8, 1719.	3.5	27
160	p38 Mitogen Activated Protein Kinase Controls Two Successive-Steps During the Early Mesodermal Commitment of Embryonic Stem Cells. Stem Cells and Development, 2011, 20, 1233-1246.	2.1	26
161	Diet Modulates Endogenous Thrombin Generation, A Biological Estimate of Thrombosis Risk, Independently of the Metabolic Status. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2394-2404.	2.4	26
162	Recent advances in the pharmacogenetics of clopidogrel. Human Genetics, 2012, 131, 653-664.	3.8	26

#	Article	IF	Citations
163	Clinical and Laboratory Findings in Patients with Î´-Storage Pool Disease: A Case Series. Seminars in Thrombosis and Hemostasis, 2017, 43, 048-058.	2.7	26
164	Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization. Thrombosis and Haemostasis, 1994, 72, 931-936.	3.4	26
165	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thrombosis and Haemostasis, 2007, 98, 838-43.	3.4	26
166	Plasminogen activator inhibitor activity in various types of endogenous hypertriglyceridemia. Fibrinolysis, 1993, 7, 171-176.	0.5	25
167	Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937. Blood, 1996, 87, 162-173.	1.4	25
168	Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis, 2005, 179, 317-323.	0.8	25
169	Intracellular Calcium Mobilization Suppresses the TNF-Î±â€“Stimulated Synthesis of PAI-1 in Human Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1550-1560.	2.4	25
170	Fibrinolysis in insulin dependent diabetic patients with or without nephropathy. Fibrinolysis, 1992, 6, 105-109.	0.5	24
171	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thrombosis Research, 2010, 126, e400-e402.	1.7	24
172	Epicardial Fat Volume Is Associated With Coronary Microvascular Response in Healthy Subjects: A Pilot Study. Obesity, 2012, 20, 1200-1205.	3.0	24
173	Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. International Journal of Cardiology, 2013, 170, e21-e22.	1.7	24
174	Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. Fibrinolysis, 1995, 9, 237-242.	0.5	23
175	Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. Journal of Thrombosis and Haemostasis, 2009, 7, 1939-1941.	3.8	23
176	Early matrix metalloproteinase-9 concentration in the first 48â€Šh after aneurysmal subarachnoid haemorrhage predicts delayed cerebral ischaemia. European Journal of Anaesthesiology, 2016, 33, 662-669.	1.7	23
177	New Direct Assay of Free Protein S Antigen Applied to Diagnosis of Protein S Deficiency. Thrombosis and Haemostasis, 1996, 75, 283-285.	3.4	23
178	Perioperative Open-lung Approach, Regional Ventilation, and Lung Injury in Cardiac Surgery. Anesthesiology, 2020, 133, 1029-1045.	2.5	23
179	Iloprost and salvage of a free flap. Journal of Plastic, Reconstructive and Aesthetic Surgery, 1996, 49, 245-248.	1.1	22
180	Relationship of Plasminogen Activator Inhibitor-1 Levels following Thrombolytic Therapy with rt-PA as Compared to Streptokinase and Patency of Infarct Related Coronary Artery. Thrombosis and Haemostasis, 1999, 82, 104-108.	3.4	22

#	Article	IF	Citations
181	Characterization of Epitheloid Cells from Human Omentum: Comparison with Endothelial Cells from Umbilical Veins. Thrombosis and Haemostasis, 1991, 66, 361-367.	3.4	22
182	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. International Journal of Cardiology, 2013, 168, 523-528.	1.7	21
183	Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. International Journal of Cardiology, 2014, 176, 1200-1202.	1.7	21
184	Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome. Blood, 2015, 126, 1967-1969.	1.4	21
185	Hysteresis-like binding of coagulation factors X/Xa to procoagulant activated platelets and phospholipids results from multistep association and membrane-dependent multimerization. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 1216-1227.	2.6	21
186	The Transcriptional Effects of PCB118 and PCB153 on the Liver, Adipose Tissue, Muscle and Colon of Mice: Highlighting of Glut4 and Lipin1 as Main Target Genes for PCB Induced Metabolic Disorders. PLoS ONE, 2015, 10, e0128847.	2.5	21
187	Long-term management of leukocyte adhesion deficiency type III without hematopoietic stem cell transplantation. Haematologica, 2018, 103, e264-e267.	3.5	20
188	Strengths and Weaknesses of Light Transmission Aggregometry in Diagnosing Hereditary Platelet Function Disorders. Journal of Clinical Medicine, 2020, 9, 763.	2.4	20
189	RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology. International Journal of Molecular Sciences, 2020, 21, 1075.	4.1	20
190	Up-Regulated Expression of Plasminogen Activator Inhibitor-1 in Hep G2 Cells: Interrelationship between Insulin and Insulin-Like Growth Factor 1. Thrombosis and Haemostasis, 1995, 73, 268-274.	3.4	20
191	4 Pathophysiology of fibrinolysis. Best Practice and Research: Clinical Haematology, 1995, 8, 329-343.	1.1	19
192	Formation, Inhibition and Clearance of Plasmin in vivo. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 204-218.	0.3	19
193	ABO Blood Group and von Willebrand Factor Levels Partially Explained the Incomplete Penetrance of Congenital Thrombophilia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2021-2028.	2.4	19
194	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
195	Tiplaxtinin impairs nutritionally induced obesity in mice. Thrombosis and Haemostasis, 2006, 96, 731-737.	3.4	19
196	Effect of low density lipoproteins on secretion of plasminogen activator inhibitor-1 (PAI-1) by human endothelial cells and hepatoma cells. Fibrinolysis, 1990, 4, 82-83.	0.5	18
197	Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma. Thrombosis Research, 1991, 62, 275-285.	1.7	18
198	Comparison of Platelet Reactivity and Clopidogrel Response in Patients â‰¥75 Years Versus >75 Years Undergoing Percutaneous Coronary Intervention for Nonâ€“ST-Segment Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2011, 108, 1411-1416.	1.6	18

#	Article	IF	Citations
199	Circulating Matrix Metalloproteinases in Infective Endocarditis: A Possible Marker of the Embolic Risk. PLoS ONE, 2011, 6, e18830.	2.5	18
200	MRI follow-up of TNF-dependent differential progression of atherosclerotic wall-thickening in mouse aortic arch from early to advanced stages. Atherosclerosis, 2007, 195, e93-e99.	0.8	17
201	Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. Journal of Thrombosis and Haemostasis, 2010, 8, 942-949.	3.8	17
202	Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseillesâ€NImes prediction model. Journal of Thrombosis and Haemostasis, 2014, 12, 138-146.	3.8	17
203	Modulation of T Cell Activation in Obesity. Antioxidants and Redox Signaling, 2017, 26, 489-500.	5.4	17
204	Antiâ€Î±_{IIb}Î²₃ immunization in Glanzmann thrombasthenia: review of literature and treatment recommendations. British Journal of Haematology, 2018, 181, 173-182.	2.5	17
205	Mutations of the integrin Î±IIb/Î²3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet Î±â€granules. American Journal of Hematology, 2018, 93, 195-204.	4.1	17
206	Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i. Platelets, 2018, 29, 95-97.	2.3	17
207	Caution in Interpreting Results from Imputation Analysis When Linkage Disequilibrium Extends over a Large Distance: A Case Study on Venous Thrombosis. PLoS ONE, 2012, 7, e38538.	2.5	17
208	CD11b+ leukocyte microparticles are associated with highâ€risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. Journal of Thrombosis and Haemostasis, 2011, 9, 1870-1873.	3.8	16
209	Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome. Cerebrovascular Diseases, 2016, 42, 404-414.	1.7	16
210	Antiviral activity of formyl peptide receptor 2 antagonists against influenza viruses. Antiviral Research, 2017, 143, 252-261.	4.1	16
211	Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates. Blood, 2021, 137, 2256-2266.	1.4	16
212	Effectiveness of switching â€˜hyper respondersâ€™ from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. International Journal of Cardiology, 2013, 168, 5004-5005.	1.7	15
213	An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology, 2020, 52, 243-255.	0.6	15
214	Severe thrombophilia in a factor Vâ€deficient patient homozygous for the Ala2086Asp mutation (FV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.8	15
215	A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant. Thrombosis and Haemostasis, 1998, 80, 859-860.	3.4	14
216	Heterogeneity of anti-Î²2-glycoprotein I antibodies. Thrombosis and Haemostasis, 2005, 93, 80-87.	3.4	14

#	Article	IF	Citations
217	Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung. Journal of Thrombosis and Haemostasis, 2007, 5, 2467-2475.	3.8	14
218	Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk. Scientific Reports, 2017, 7, 45507.	3.3	14
219	Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAGâ€GEFI encoding gene. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 128-133.	2.3	14
220	Proteaseâ€activated receptor 1 inhibition protects mice against thrombinâ€dependent respiratory syncytial virus and human metapneumovirus infections. British Journal of Pharmacology, 2018, 175, 388-403.	5.4	14
221	Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR. Thrombosis and Haemostasis, 1999, 81, 463-463.	3.4	13
222	Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. Journal of Thrombosis and Haemostasis, 2008, 6, 1975-1977.	3.8	13
223	Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder. International Journal of Cardiology, 2010, 138, 212-213.	1.7	13
224	Fixed-dose aspirinâ€“clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. International Journal of Cardiology, 2014, 172, e1-e2.	1.7	13
225	CD28 deletion improves obesity-induced liver steatosis but increases adiposity in mice. International Journal of Obesity, 2015, 39, 977-985.	3.4	13
226	Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia. Platelets, 2016, 27, 828-829.	2.3	13
227	Augmenting pharmacotherapy with neuromodulation techniques for the treatment of bipolar disorder: a focus on the effects of mood stabilizers on cortical excitability. Expert Opinion on Pharmacotherapy, 2019, 20, 1575-1588.	1.8	13
228	Binding of Coagulation Factor XIII Zymogen to Activated Platelet Subpopulations: Roles of Integrin Î±IIbÎ²3 and Fibrinogen. Thrombosis and Haemostasis, 2019, 119, 906-915.	3.4	13
229	Relation between Plasma PAI Activity and Adipsin Levels. Thrombosis and Haemostasis, 1995, 74, 1200-1202.	3.4	13
230	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thrombosis Research, 2012, 130, 70-74.	1.7	12
231	Multilevel systems biology modeling characterized the atheroprotective efficiencies of modified dairy fats in a hamster model. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H935-H945.	3.2	12
232	The Annexin A1 Receptor FPR2 Regulates the Endosomal Export of Influenza Virus. International Journal of Molecular Sciences, 2018, 19, 1400.	4.1	12
233	Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus. Thrombosis and Haemostasis, 1997, 78, 1416-1417.	3.4	12
234	The Plasminogen Activation System Modulates Differently Adipogenesis and Myogenesis of Embryonic Stem Cells. PLoS ONE, 2012, 7, e49065.	2.5	12

#	Article	IF	Citations
235	Increased levels of the megakaryocyte and platelet expressed cysteine proteases stefin A and cystatin A prevent thrombosis. Scientific Reports, 2019, 9, 9631.	3.3	11
236	Plasminogen activator inhibitor type-1 is an independent marker of metabolic disorders in young adults born small for gestational age. Journal of Thrombosis and Haemostasis, 2010, 8, 2608-2613.	3.8	10
237	Systemic inhibition and liverâ€specific overâ€expression of PAIâ€1 failed to improve survival in allâ€inclusive populations or homogenous cohorts of CLP mice. Journal of Thrombosis and Haemostasis, 2014, 12, 958-969.	3.8	10
238	Effectiveness of switching â€˜low respondersâ€™ to prasugrel to ticagrelor after acute coronary syndrome. International Journal of Cardiology, 2014, 176, 1184-1185.	1.7	10
239	Common Risk Factors Add to Inherited Thrombophilia to Predict Venous Thromboembolism Risk in Families. TH Open, 2019, 03, e28-e35.	1.4	10
240	Thromboxaneâ€“prostaglandin receptor antagonist, terutroban, prevents neurovascular events after subarachnoid haemorrhage: a nanoSPECT study in rats. Critical Care, 2019, 23, 42.	5.8	10
241	Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. European Journal of Pharmacology, 2020, 866, 172798.	3.5	10
242	Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. Thrombosis and Haemostasis, 2007, 97, 62-66.	3.4	10
243	Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome. Thrombosis and Haemostasis, 2010, 103, 774-779.	3.4	9
244	InÂVivo Assessment of Murine Elastase-induced Abdominal Aortic Aneurysm with High Resolution Magnetic Resonance Imaging. European Journal of Vascular and Endovascular Surgery, 2012, 44, 475-481.	1.5	9
245	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. American Heart Journal, 2012, 164, 327-333.	2.7	8
246	A new heterozygous mutation in <scp>GP</scp>1<scp>BA</scp> gene responsible for macrothrombocytopenia. British Journal of Haematology, 2018, 183, 503-506.	2.5	8
247	Platelets: a potential role in chronic respiratory diseases?. European Respiratory Review, 2021, 30, 210062.	7.1	8
248	Relevance of Free tPA Assay Following Venous Occlusion in Patients with Venous Thromboembolic Disease. Thrombosis and Haemostasis, 1988, 59, 346-347.	3.4	8
249	Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. International Journal of Cardiology, 2013, 168, 2988-2989.	1.7	7
250	Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. Annales De Cardiologie Et D'Angeiologie, 2014, 63, 222-227.	0.6	7
251	Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors. International Journal of Cardiology, 2015, 184, 428-430.	1.7	7
252	Genetic risk factors for venous thrombosis in women using combined oral contraceptives: update of the <scp>PILGRIM</scp> study. Clinical Genetics, 2017, 91, 131-136.	2.0	7

#	Article	IF	Citations
253	Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation. Scientific Reports, 2019, 9, 3750.	3.3	7
254	Platelets Purification Is a Crucial Step for Transcriptomic Analysis. International Journal of Molecular Sciences, 2022, 23, 3100.	4.1	7
255	The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; Comparison with other methods. Fibrinolysis, 1990, 4, 177-181.	0.5	6
256	Î² -thalassaemia-87 Câ†'G: relationship of the Hb F modulation and polymorphisms in compound heterozygous patients. British Journal of Haematology, 2004, 126, 743-749.	2.5	6
257	A 13 base pair deletion in the GPIbÎ² gene in a second unrelated Bernard-Soulier family due to slipped mispairing between direct repeats. Journal of Thrombosis and Haemostasis, 2004, 2, 1663-1665.	3.8	6
258	Laboratory Techniques Used to Diagnose Constitutional Platelet Dysfunction. Hamostaseologie, 2020, 40, 444-459.	1.9	6
259	GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis. Journal of Thrombosis and Haemostasis, 2021, 19, 2287-2301.	3.8	6
260	Purpura Fulminans in a Patient Homozygous for a Mutation in the Protein C Gene - Prenatal Diagnosis in a Subsequent Pregnancy. Thrombosis and Haemostasis, 1996, 75, 525-526.	3.4	6
261	Intraperitoneal Insulin Administration Does Not Modify Plasminogen Activator Inhibitor 1 Levels in IDDM Patients. Diabetes Care, 1994, 17, 941-942.	8.6	5
262	Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study. Journal of Molecular Medicine, 2010, 88, 193-201.	3.9	5
263	Peripartum bleeding management in a patient with Cal<scp>DAG</scp>â€<scp>GEFI</scp> deficiency. Haemophilia, 2017, 23, e533-e535.	2.1	5
264	A Novel Rapid Method of Red Blood Cell and Platelet Permeabilization and Staining for Flow Cytometry Analysis. Cytometry Part B - Clinical Cytometry, 2019, 96, 426-435.	1.5	5
265	Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Journal of Thrombosis and Haemostasis, 2019, 17, 2188-2195.	3.8	5
266	NovelACTN1variants in cases of thrombocytopenia. Human Mutation, 2019, 40, 2258-2269.	2.5	5
267	PAI-1, Obesity, and Insulin Resistance. , 1999, , 317-332.		5
268	Venous Occlusion Does Not Induce the Release of Thrombomodulin from Endothelial Cells in Patients with Thromboembolic Disease. Thrombosis and Haemostasis, 1992, 68, 483-484.	3.4	5
269	SystÃ¨me fibrinolytique, mÃ©talloproteases et pathologie vasculaire.. Medecine/Sciences, 2001, 17, 170.	0.2	5
270	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thrombosis and Haemostasis, 2007, 97, 212-7.	3.4	5

#	Article	IF	Citations
271	PPARÎ± deficiency does not modify age dependency but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance. Thrombosis and Haemostasis, 2004, 91, 1051-1052.	3.4	4
272	TAFI levels in patients with acute myocardial infarction treated with thrombolysis. Journal of Thrombosis and Haemostasis, 2005, 3, 395-397.	3.8	4
273	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. International Journal of Cardiology Heart & Vessels, 2014, 4, 188-192.	0.5	4
274	Î±1-antitrypsin Pittsburgh and plasmin-mediated proteolysis. Journal of Thrombosis and Haemostasis, 2016, 14, 2023-2026.	3.8	4
275	Immediate Postnatal Overfeeding in Rats Programs Aortic Wall Structure Alterations and Metalloproteinases Dysregulation in Adulthood. American Journal of Hypertension, 2016, 29, 719-726.	2.0	4
276	Î´-storage pool disease: an underestimated cause of unexplained bleeding. Hematologie, 2017, 23, 243-254.	0.0	4
277	Platelet CD 40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 684-694.	2.3	4
278	Cutaneous Necrosis Associated with Acquired Severe Protein S Deficiency. Thrombosis and Haemostasis, 1994, 71, 396-396.	3.4	4
279	PAI-1 and the Risk of Cardiovascular Disease. Medical Science Symposia Series, 1998, , 85-92.	0.0	4
280	Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: The prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). Thrombosis Research, 2010, 126, e397-e399.	1.7	3
281	Pathophysiology of inherited platelet disorders. Hematologie, 2014, 20, 20-35.	0.0	3
282	Hematopoietic stem cell transplantation for the treatment of leukocyte adhesion deficiency type III. Pediatrics and Neonatology, 2017, 58, 560-561.	0.9	3
283	A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males. Molecular Nutrition and Food Research, 2020, 64, 2000480.	3.3	3
284	On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Thrombosis and Haemostasis, 2021, 121, 923-930.	3.4	3
285	Plasma Plasminogen Activator Inhibitor Activity in Rats with Nutritionally Induced Insulin Resistance. Thrombosis and Haemostasis, 1995, 74, 806-807.	3.4	3
286	Potentiation by Heparin Fragment CY 222 (CHOAY) of Thrombolysis Induced by Human Tissue-Type Plasminogen Activator. Seminars in Thrombosis and Hemostasis, 1989, 15, 390-394.	2.7	2
287	Anti-phospholipid/cofactor antibodies in three cases of persistent polyclonal b lymphocytosis. British Journal of Haematology, 2002, 119, 875-876.	2.5	2
288	Adjusting Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Index: On Time, Too Early, or Too Late?. Journal of the American College of Cardiology, 2008, 52, 790-791.	2.8	2

#	Article	IF	Citations
289	Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome. International Journal of Cardiology, 2013, 168, 1565-1566.	1.7	2
290	The first intracellular loop of GLUT4 contains a retention motif. Journal of Cell Science, 2016, 129, 2273-84.	2.0	2
291	High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome. Atherosclerosis, 2020, 293, 86-91.	0.8	2
292	Contribution of exome sequencing to the identification of genes involved in the response to clopidogrel in cardiovascular patients. Journal of Thrombosis and Haemostasis, 2020, 18, 1425-1434.	3.8	2
293	A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant. PLoS Genetics, 2021, 17, e1009284.	3.5	2
294	Relations between hemostatic variables, insulin resistance and inflammation. The Hematology Journal, 2004, 5, S15-S19.	1.4	2
295	Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia. Endocrine Connections, 2019, 8, 349-359.	1.9	2
296	Screening platelet function in blood donors. Transfusion, 0, , .	1.6	2
297	Lupus anticoagulants and antiphospholipid antibodies: Comparison of clotting tests with an immunological assay. Thrombosis Research, 1990, 60, 181-183.	1.7	1
298	Variables of the fibrinolytic system: risk indicators for CHD. Fibrinolysis and Proteolysis, 1997, 11, 47-49.	1.1	1
299	High Residual Platelet Reactivity and Thrombotic Events. JAMA - Journal of the American Medical Association, 2011, 306, 2561-2561.	7.4	1
300	Obesity and vascular disease: From bench to bedside. Thrombosis and Haemostasis, 2013, 110, 632-633.	3.4	1
301	Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. Platelets, 2016, 27, 791-795.	2.3	1
302	Bernardâ€“Soulier syndrome: first human case due to a homozygous deletion of GP9 gene. British Journal of Haematology, 2020, 188, e87-e90.	2.5	1
303	Phenotype Analysis and Clinical Management in a Large Family with a Novel Truncating Mutation in RASGRP2, the Caldag-GEFI Encoding Gene. Blood, 2016, 128, 3713-3713.	1.4	1
304	Strengths and weaknesses of platelet aggregation in diagnosis of hereditary platelet disorders. Hematologie, 2017, 23, 298-311.	0.0	1
305	RELEVANCE OF FREE t-PA ASSAY FOLLOWING VENOUS OCCLUSION IN PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE. , 1987, 58, 1627.		0
306	EFFECT OF DIFFERENT HEPARINS ON THROMBOLYSIS WITH t-PA AND scu-PA IN RABBITS WITH EXPERIMENTAL THROMBOSIS. , 1987, 58, 0993.		0

#	Article	IF	Citations
307	Lupus anticoagulant in silica-induced scleroderma. Clinical Rheumatology, 1992, 11, 444-445.	2.2	0
308	2.W14.3 Impaired fibrinolysis and the risk of CHD. Atherosclerosis, 1997, 134, 111.	0.8	0
309	Regulation of PAI-1 in obesity and insulin resistance. Atherosclerosis, 1999, 144, 14.	0.8	0
310	Les statines en thÃ©rapeutique cardiovasculaire. Medecine/Sciences, 2002, 18, 1257-1265.	0.2	0
311	PCV18 WHEN SHOULD PATIENTS BE SWITCHED FROMVKATO NEW TREATMENT: DEVELOPMENT AND PILOT TESTING OF A SELF-REPORTED QUESTIONNAIRE TO TARGET PATIENTS WHO WOULD BENEFIT MOST. Value in Health, 2005, 8, A94.	0.3	0
312	Tu-W19:2 Role of the fibrinolytic system in the development of obesity and the metabolic syndrome. Atherosclerosis Supplements, 2006, 7, 158.	1.2	0
313	Lipides peroxydÃ©s et rÃ©action immuno-inflammatoire dans lâ€™athÃ©rosclÃ©rose. Oleagineux Corps Gras Lipides, 2006, 13, 337-342.	0.2	0
314	Tissu adipeux viscÃ©ral et thrombose. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2008, 2008, 19-27.	0.0	0
315	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. American Journal of Human Genetics, 2010, 86, 655.	6.2	0
316	Glycemic control and clopidogrel response. American Heart Journal, 2010, 159, e35.	2.7	0
317	Ã‰valuation de lâ€™expression dâ€™adipocytes humains sous-cutanÃ©s en culture aux acides linolÃ©iques conjuguÃ©s par une approche multi-omique. Oleagineux Corps Gras Lipides, 2011, 18, 365-371.	0.2	0
318	Effectiveness of switching hyper responders from prasugrel to clopidogrel after acute coronary syndrome: the POBA SWITCH study. European Heart Journal, 2013, 34, P4883-P4883.	2.2	0
319	Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (Predictor Of Bleedings with Antiplatelet drugs). European Heart Journal, 2013, 34, 4528-4528.	2.2	0
320	Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel. European Heart Journal, 2013, 34, P4878-P4878.	2.2	0
321	Pathophysiology of inherited platelet disorders. Sang Thrombose Vaisseaux, 2014, 26, 300-316.	0.1	0
322	Efficacy of terutroban in preventing delayed cerebral ischemia after subarachnoid haemorrhage: a functional isotope imaging study on a rat model. European Journal of Anaesthesiology, 2014, 31, 109.	1.7	0
323	Reply. JACC: Cardiovascular Interventions, 2014, 7, 108.	2.9	0
324	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. Pharmacogenomics, 2015, 16, 459-469.	1.3	0

#	Article	IF	Citations
325	398 Metabolic Effect in a New Experimental Model of Gastric Bypass Using Luminal Apposing Stent and Surgical Endoscopy. Gastrointestinal Endoscopy, 2016, 83, AB145.	1.0	0
326	TCT-415 Platelet Reactivity Inhibition Following Ticagrelor Loading Dose in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 74, B411.	2.8	0
327	Atypical late diagnosis of Noonan syndrome revealed by bleedings due to platelet dysfunction. Journal of Thrombosis and Thrombolysis, 2022, 53, 557-560.	2.1	0
328	First case of a humanRASGRP2mutation affecting Rap1 activation in platelets and causing severe bleeding.. Journal of Cell Biology, 2014, 206, 2061OIA111.	5.2	0
329	Alterations of the Platelet Procoagulant or Fibrinolytic Functions. , 2017, , 937-949.		0